Physician profile
Ryan Meshulam
NPI 1013200138
$2,243.10
in general payments reported to CMS, 2019-2025
15 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2021: $46.91 · 2023: $189 · 2024: $364 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.64 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.74 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.33 | 2021-2025 | Caplyta |
| Alkermes, INC. | $223.15 | 2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $219.90 | 2024-2025 | Auvelity |
| Allergan, INC. | $151.06 | 2019 | |
| Neurocrine Biosciences, INC. | $136.15 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $126.78 | 2024-2025 | Rexulti |
| Lundbeck LLC | $115.07 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $111.49 | 2024 | |
| Corium, LLC | $70.97 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $50.37 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $43.86 | 2025 | Cobenfy |
| Neuronetics, INC. | $31.39 | 2024 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $20.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.84 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Meshulam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.